311 related articles for article (PubMed ID: 29074161)
21. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
[TBL] [Abstract][Full Text] [Related]
22. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials.
Varma R; Bressler NM; Suñer I; Lee P; Dolan CM; Ward J; Colman S; Rubio RG;
Ophthalmology; 2012 Oct; 119(10):2108-18. PubMed ID: 22817833
[TBL] [Abstract][Full Text] [Related]
23. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
24. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
[TBL] [Abstract][Full Text] [Related]
25. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
27. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion.
Cekiç O; Chang S; Tseng JJ; Barile GR; Weissman H; Del Priore LV; Schiff WM; Weiss M; Klancnik JM
Retina; 2005; 25(7):846-50. PubMed ID: 16205562
[TBL] [Abstract][Full Text] [Related]
29. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
30. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.
Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C
Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576
[TBL] [Abstract][Full Text] [Related]
31. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
Hu Q; Li H; Xu W; Du Y; Ma C; He J
Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
[TBL] [Abstract][Full Text] [Related]
32. SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Figueroa M;
Am J Ophthalmol; 2016 Oct; 170():25-31. PubMed ID: 27450625
[TBL] [Abstract][Full Text] [Related]
33. Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.
Khurana RN; Oden NL; VanVeldhuisen PC; Scott IU; Blodi BA; Ip MS;
Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):1839-1851. PubMed ID: 33415354
[TBL] [Abstract][Full Text] [Related]
34. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
[TBL] [Abstract][Full Text] [Related]
36. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
37. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
Boyer D; Heier J; Brown DM; Clark WL; Vitti R; Berliner AJ; Groetzbach G; Zeitz O; Sandbrink R; Zhu X; Beckmann K; Haller JA
Ophthalmology; 2012 May; 119(5):1024-32. PubMed ID: 22440275
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
[TBL] [Abstract][Full Text] [Related]
40. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
